10 Merck executives
Chairman and CEO, CFO, general counsel, chief technology officer and the chief medical officer of Merck Research Laboratories are represented among these Merck executives, alongside the heads of manufacturing, global oncology and international, vaccines, and the specialty, pharma and infectious diseases business. Questions about how a large drugmaker divides research, manufacturing and commercial leadership fit them well; only Michael Klobuchar's Merck role has an end date.
Professionals to explore
Brian Foard
LinkedInExperience: Executive Vice President and President, Specialty, Pharma, & Infectious Diseases · Merck
$5,385 per 30-minute call
Brian Foard has been Executive Vice President and President, Specialty, Pharma, & Infectious Diseases at Merck since March 2026. Sanofi roles came before: Executive Vice President, Specialty Care (2024–2026), Head, Specialty Care North America, U.S. Country Lead (2023–2024) and Global Franchise Head Immunology (2020–2023), so questions comparing how two drugmakers build specialty franchises fit well.
Is this you? Claim your profile and get paid for calls.
Caroline Litchfield
LinkedInExperience: Chief Financial Officer · Merck
$3,029 per 30-minute call
Chief Financial Officer of Merck since April 2021, Caroline Litchfield is responsible for the company's finance, procurement and real estate operations. As Senior Vice President & Treasurer (2019–2021) the remit covered treasury, tax and investor relations, and Senior Vice President Finance - Global Human Health (2014–2018) adds the finance side of a commercial business.
Is this you? Claim your profile and get paid for calls.
Eliav Barr
LinkedInExperience: Head, Global Clinical Development and Chief Medical Officer, Merck Research Laboratories · Merck
$5,385 per 30-minute call
Late-stage clinical development for the whole portfolio and pipeline is led by Eliav Barr, Head, Global Clinical Development and Chief Medical Officer, Merck Research Laboratories since 2022, who also lists Senior Vice President Global Medical and Scientific Affairs since 2018. Past titles include Senior Vice President, Vaccines and Infectious Diseases Global Clinical Development (2016–2018), Vice President, Infectious Diseases (2011–2016) and Vice President Oncology (2008–2011).
Is this you? Claim your profile and get paid for calls.
Fran Geatens
LinkedInExperience: Chief Technology Officer & Senior Vice President · Merck
$4,039 per 30-minute call
Fran Geatens holds the Chief Technology Officer & Senior Vice President role at Merck, dated from July 2025, accountable for the company's long-term technology vision and strategy. Other Merck titles are VP, Technology Infrastructure, Operations, & Experience (2019–2025), Executive Director, Enterprise Platforms (2014–2019) and Executive Director, Supply Chain Management IT (2011–2013), useful for questions on enterprise technology platforms in pharma.
Is this you? Claim your profile and get paid for calls.
Gregg Szabo
LinkedInExperience: Senior Vice President, Merck, and President, Global Vaccines & Infectious Diseases · Merck
$4,039 per 30-minute call
Gregg Szabo became Senior Vice President, Merck, and President, Global Vaccines & Infectious Diseases in November 2025. Before that came a run of global commercial roles at Merck: VP and Global Commercial Leader, HPV Vaccines (2023–2025), Hospital & Infectious Disease (2022–2023), Virology Immunology (2019–2022) and Virology (2018–2019), a fit for questions on commercializing a vaccine portfolio worldwide.
Is this you? Claim your profile and get paid for calls.
Jannie Oosthuizen
LinkedInExperience: President Global Oncology & MSD International · Merck
$5,385 per 30-minute call
President Global Oncology & MSD International at Merck since April 2026, Jannie Oosthuizen was President, Merck Human Health U.S. (2022–2026), President Merck Global Oncology (2021) and SVP President MSD Japan (2016–2020). The record describes managing P&Ls across multiple countries, product launches and lifecycle management, which points to questions on launching oncology products in the U.S. and abroad.
Is this you? Claim your profile and get paid for calls.
Jennifer Zachary
LinkedInExperience: Executive Vice President and General Counsel · Merck
$4,039 per 30-minute call
As Executive Vice President and General Counsel at Merck since April 2018, Jennifer Zachary is the company's chief legal advisor and also leads the Environment, Health & Safety and Global Security organizations. Prior roles include Partner at Covington & Burling LLP (2013–2018) and Associate Chief Counsel at the FDA (2005–2011), a background suited to regulatory and legal strategy questions in pharma.
Is this you? Claim your profile and get paid for calls.
Michael Klobuchar
LinkedInExperience: Former Executive Vice President, Chief Strategy Officer · Merck
$4,039 per 30-minute call
Now Chief Operating Officer at Eikon Therapeutics (since 2024), Michael Klobuchar was Executive Vice President, Chief Strategy Officer at Merck (2021–2024). Merck roles before that were Senior Vice President, CFO COO of Merck R&D, Head of Global Portfolio and Alliance Management (2019–2021) and President of Emerging Businesses and Senior Vice President, Corporate Strategy and Planning (2014–2019), relevant to portfolio, alliance and strategy questions.
Is this you? Claim your profile and get paid for calls.
Rob Davis
LinkedInExperience: Chairman and Chief Executive Officer · Merck
$13,461 per 30-minute call
Rob Davis has been Chairman and Chief Executive Officer of Merck since December 2022, after Chief Executive Officer and President (2021–2022) and President (2021). The record also shows Executive Vice President, Global Services and Chief Financial Officer (2016–2021) and Executive Vice President and Chief Financial Officer (2014–2016), which makes Rob Davis a fit for questions on moving from running finance to running the whole company.
Is this you? Claim your profile and get paid for calls.
Sanat Chattopadhyay
LinkedInExperience: Executive Vice President & President, Merck Manufacturing Division · Merck
$4,039 per 30-minute call
Worldwide manufacturing and supply operations are the responsibility described by Sanat Chattopadhyay as Executive Vice President & President, Merck Manufacturing Division from April 2016, a role that includes a seat on the executive committee and that their LinkedIn profile now calls former. Earlier Merck titles were Senior Vice President, Global Manufacturing Operations (Human Health) (2014–2016) and Senior VP, Biologics, Vaccines & Sterile Manufacturing (2012–2014).
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
Commercial questions about launching or running a franchise belong with the three business presidents, Brian Foard, Jannie Oosthuizen and Gregg Szabo; manufacturing and supply go to Sanat Chattopadhyay, and clinical development to Eliav Barr. Corporate questions split by function: finance and treasury with Caroline Litchfield or Rob Davis, who was CFO from 2014 to 2021, legal and security with Jennifer Zachary, technology with Fran Geatens, and portfolio strategy with Michael Klobuchar, who left Merck in 2024.
Questions to take into the conversation
- 01How do you decide which late-stage programs get funding when oncology, vaccines and infectious disease compete for the same budget?
- 02What does it take to run worldwide manufacturing and supply for pharmaceuticals, biologics and vaccines from one division?
- 03How should a large drugmaker split commercial leadership between its U.S. business and its international markets?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.